A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis

Background Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Preliminary study results suggest that oclacitinib, a selective Janus kinase inhibitor, could reduce pruritus and associated inflammatory skin lesions in dogs with AD. Hypothesis/Objectives The objective was to eval...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Veterinary dermatology 2013-12, Vol.24 (6), p.587-e142
Hauptverfasser:	Cosgrove, Sallie B., Wren, Jody A., Cleaver, Dawn M., Walsh, Kelly F., Follis, Stacey I., King, Vickie I., Tena, Jezaniah-Kira S., Stegemann, Michael R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Dermatitis, Atopic - drug therapy Dermatitis, Atopic - veterinary Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Dog Diseases - drug therapy Dogs Female Male Pyrimidines - adverse effects Pyrimidines - therapeutic use Scientific Paper Scientific Papers Sulfonamides - adverse effects Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!